SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 21st, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 21st, 2017 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of September 20, 2017, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:Letter Agreement • September 21st, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 21st, 2017 Company Industry JurisdictionThis letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • September 21st, 2017 • Pharmaceutical preparations • New York
Company FiledSeptember 21st, 2017 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ___1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).